Related Experiment Videos
BG-9928 (Biogen Idec).
1Division of Health Practice, Auckland University of Technology-Akoranga Campus, Auckland, New Zealand. sdoggrell@xtra.co.nz
Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2005
Summary
Biogen Idec is developing BG-9928, an oral adenosine A1 receptor antagonist, for treating congestive heart failure. Phase II trials were underway in early 2003 to evaluate its potential therapeutic benefits.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Congestive heart failure (CHF) remains a significant cause of morbidity and mortality.
- Adenosine A1 receptors play a role in cardiovascular function and have been targeted for CHF treatment.
Purpose of the Study:
- To investigate the potential of BG-9928, a selective oral adenosine A1 receptor antagonist, as a novel therapeutic agent for congestive heart failure.
Main Methods:
- Development of BG-9928 by Biogen Idec under license from CV Therapeutics.
- Ongoing Phase II clinical trials to assess safety and efficacy in patients with CHF.
Main Results:
- BG-9928 is a selective oral adenosine A1 receptor antagonist.
- Phase II trials were in progress as of January 2003.
Conclusions:
- BG-9928 shows promise as a potential treatment for congestive heart failure.
- Further clinical evaluation is necessary to establish its therapeutic role.